Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation

Tomita Hideharu; Araki Takuya; Kadokami Toshiaki; Yamada Satoshi; Nakamura Ryo; Imamura Yoshihiro; Fukuyama Takaya; Nagano Daisuke; Hashimoto Tomoya; Uematsu Akiko; Hosokawa Kazuya; Yamamoto Koujirou; Ueda Shin-ichiro; Ando Shin-ichi

首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation

【24h】

Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation

机译：非瓣膜性心房颤动患者低谷和90分钟血浆达比加群酯浓度的影响因素

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: Dabigatran etexilate, a direct oral anti-coagulation agent, is used in the prevention of thromboembolism in patients with non-valvular atrial fibrillation (NVAF). However, for reasons that are not fully understood, plasma dabigatran etexilate concentrations (PDC) vary significantly among patients.

机译：简介：达比加群酯是一种直接的口服抗凝剂，用于预防非瓣膜性房颤（NVAF）患者的血栓栓塞。但是，由于尚不完全清楚的原因，患者中血浆达比加群酯的浓度（PDC）差异很大。

著录项

来源
《Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis》 |2016年第null期|共7页
作者
Tomita Hideharu; Araki Takuya; Kadokami Toshiaki; Yamada Satoshi; Nakamura Ryo; Imamura Yoshihiro; Fukuyama Takaya; Nagano Daisuke; Hashimoto Tomoya; Uematsu Akiko; Hosokawa Kazuya; Yamamoto Koujirou; Ueda Shin-ichiro; Ando Shin-ichi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学;
关键词
Dabigatran; Plasma dabigatran concentration; Activated partial prothrombin time; D-dinner;

机译：达比加群;血浆达比加群浓度;激活的凝血酶原部分时间;D-晚餐;

相似文献

外文文献
中文文献
专利

1. Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation [J] . Tomita Hideharu, Araki Takuya, Kadokami Toshiaki, Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis . 2016,第Null期

机译：非瓣膜性心房颤动患者低谷和90分钟血浆达比加群酯浓度的影响因素
2. Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease [J] . Skripka Alena, Sychev Dmitriy, Bochkov Pavel, Mathematical research letters: MRL . 2020,第2期

机译：影响大鼠血浆Dabigatran浓度在心房颤动和慢性肾病患者中的因素
3. Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation [J] . N. A. Novikova, A. N. Volovchenko Racional?naa Farmakoterapia v Kardiologii . 2016,第5期

机译：非瓣膜性心房颤动患者电复律过程中达比加群酯的释放
4. Epicardial Pulmonary Vein Isolation By Cryoablation As Concomitant Cardiac Surgery To Treat Non-valvular Atrial Fibrillation "Lavie Technique" [C] . H. Kubota, M. Sato, T. Fujiki, World Congress on Cardiac Pacing and Electrophysiology . 2003

机译：心外膜肺静脉隔离通过冷冻剂作为伴随心脏手术治疗非瓣膜心房颤动“Lavie技术”
5. Optimal Post-Procedural Therapy for Patients Ineligble for Treatment with Oral Anticoagulatiion Who Undergo Left Atrial Appendage Occlusion with the Watchman Device for Non-Valvular Atrial Fibrillation [D] . Whitehead, Kristen Marie. 2020

机译：用口腔抗凝血治疗患者患者的最佳过程治疗患者患有左心房阑尾闭塞与鹰刀用于非瓣膜心房颤动
6. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation [O] . Tasuku Kuwayama, Hiroyuki Osanai, Masayoshi Ajioka, 2017

机译：质子泵抑制剂对日本非瓣膜性房颤患者血液中达比加群浓度的影响
7. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation [O] . Tasuku Kuwayama, MD, Hiroyuki Osanai, MD, Masayoshi Ajioka, MD, 2017

机译：质子泵抑制剂对日本非瓣膜性心房颤动患者血液达比加群浓度的影响

Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation

摘要

著录项

相似文献

相关主题

期刊订阅